The goal of this proposal is to elucidate the molecular mechanisms governing BubR1 protein abundance and function, and its role in the regulation of tumorigenesis and aging. Aging is the single greatest risk factor for cancer development, yet the mechanistic basis driving this interrelationship remains largely undefined. BubR1, a serine/threonine protein kinase, is involved in the spindle assembly checkpoint (SAC) to ensure faithful chromosome segregation during mitosis, and therefore is intimately linked to genomic integrity and cancer. Interestingly, recent studies have implicated BubR1 in the aging process where BubR1 abundance has been shown to decline in a variety of tissues as mammals age. Mice engineered to express low levels of BubR1 from birth die within a year, exhibiting increased senescence, premature aging phenotypes and an increased susceptibility to cancer, whereas mice overexpressing BubR1 have an extended lifespan with reduction in age- related diseases and cancer development. Senescence is believed to be largely tumor-suppressive and prevent cancer in young individuals. However, in aged individuals senescent cells can contribute to age-related cancer development. Therefore, BubR1 may play a pivotal role in the interrelationship between aging and cancer given that BubR1 suppresses both senescence and tumorigenesis. Previously, we identified an acetylation-dependent mechanism regulating BubR1 protein stability, where SIRT2 prevents degradation of BubR1 through deacetylation, leading to lifespan extension of a BubR1 premature aging mouse model. Furthermore, BubR1 protein levels in aged animals can be restored to youthful levels by stimulating SIRT2 activity through induction of NAD+ levels. These results suggest that the age-related decline in BubR1 levels can be reversed, potentially alleviating age-related diseases including cancer. Therefore, we hypothesize that BubR1 is a key tumor suppressor, and its loss with age increases cancer susceptibility. In this proposal, we plan to: 1) elucidate the physiological role of BubR1 post translational modifications during aging and calorie restriction and their impact on mitotic progression and tumorigenesis; and 2) determine the mechanisms regulating BubR1 protein abundance and function during aging. These studies will elucidate how regulation of BubR1 by post-translational modifications controls mitotic progression and tumorigenesis during aging as well as to identify mechanisms through which BubR1 declines with age and controls the aging processes. Given that aging poses the largest single risk factor for developing cancer, elucidating the molecular details governing the physiological role of BubR1 in cancer and aging will provide mechanistic understanding of the interrelationship between aging and cancer development, as well as identify possible therapeutic strategies to treat age-related diseases.

Public Health Relevance

Faithful segregation of genetic material is critically important for cells to prevent tumorigenesis. During mitosis, BubR1 delays the onset of anaphase until each chromosome is properly aligned at the metaphase plate for proper attached to bipolar spindles, and loss of BubR1 therefore leads to aneuploidy and an increased incidence of cancer. Interestingly, recent studies have also shed light on a role for BubR1 in regulating the aging process by controlling cellular senescence. Age is one of the greatest risk factors for cancer, and results from the proposed studies will provide a greater understanding of the molecular mechanisms driving the interrelationship between aging and cancer, thereby providing impetus for more specific therapeutic targets for age-related diseases such as cancer.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Scientist Development Award - Research & Training (K01)
Project #
5K01AG052627-02
Application #
9353713
Study Section
Biological Aging Review Committee (NIA-B)
Program Officer
Velazquez, Jose M
Project Start
2016-09-30
Project End
2021-04-30
Budget Start
2017-05-15
Budget End
2018-04-30
Support Year
2
Fiscal Year
2017
Total Cost
$123,903
Indirect Cost
$9,178
Name
Beth Israel Deaconess Medical Center
Department
Type
Independent Hospitals
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Ci, Yanpeng; Li, Xiaoning; Chen, Maorong et al. (2018) SCF?-TRCP E3 ubiquitin ligase targets the tumor suppressor ZNRF3 for ubiquitination and degradation. Protein Cell 9:879-889
Guo, Jianping; Cheng, Ji; North, Brian J et al. (2017) Functional analyses of major cancer-related signaling pathways in Alzheimer's disease etiology. Biochim Biophys Acta Rev Cancer 1868:341-358
Shimizu, Kouhei; Fukushima, Hidefumi; Ogura, Kohei et al. (2017) The SCF?-TRCP E3 ubiquitin ligase complex targets Lipin1 for ubiquitination and degradation to promote hepatic lipogenesis. Sci Signal 10:
Tan, Yuyong; Ci, Yanpeng; Dai, Xiangpeng et al. (2017) Cullin 3SPOP ubiquitin E3 ligase promotes the poly-ubiquitination and degradation of HDAC6. Oncotarget 8:47890-47901
Nihira, Naoe T; Ogura, Kohei; Shimizu, Kouhei et al. (2017) Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function. Sci Signal 10: